Jacobs Levy Equity Management
LAB icon

Jacobs Levy Equity Management’s Standard BioTools LAB Stock Holding History

Jacobs Levy Equity Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-253,538
Closed -$1.88M – 1058
2020
Q3 		$1.88M Sell
253,538
-166,620
-40% -$1.15M 0.02% 531
2020
Q2 		$1.69M Buy
420,158
+41,748
+11% +$145K 0.02% 559
2020
Q1 		$961K Sell
378,410
-522,695
-58% -$1.72M 0.01% 627
2019
Q4 		$3.14M Buy
901,105
+771,906
+597% +$2.72M 0.03% 460
2019
Q3 		$598K Buy
129,199
+97,000
+301% +$764K 0.01% 693
2019
Q2 		$397K Sell
32,199
-249,996
-89% -$3.18M 0.01% 776
2019
Q1 		$3.75M Buy
282,195
+52,100
+23% +$549K 0.05% 384
2018
Q4 		$1.98M Sell
230,095
-13,852
-6% -$108K 0.03% 463
2018
Q3 		$1.83M Sell
243,947
-11,345
-4% -$80.7K 0.03% 539
2018
Q2 		$1.52M Buy
255,292
+9,791
+4% +$55.8K 0.02% 558
2018
Q1 		$1.43M Buy
245,501
+4,300
+2% +$28.2K 0.02% 550
2017
Q4 		$1.42M Buy
241,201
+3,100
+1% +$17K 0.03% 541
2017
Q3 		$1.2M Buy
238,101
+36,850
+18% +$155K 0.02% 545
2017
Q2 		$813K Buy
201,251
+24,700
+14% +$117K 0.02% 603
2017
Q1 		$1M Buy
176,551
+120,251
+214% +$762K 0.02% 554
2016
Q4 		$410K Buy
56,300
+10,300
+22% +$64.7K 0.01% 717
2016
Q3 		$368K Hold
46,000
– – 0.01% 766
2016
Q2 		$415K Hold
46,000
– – 0.01% 804
2016
Q1 		$371K Buy
+46,000
New +$332K 0.01% 812

Other funds holding LAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Jacobs Levy Equity Management's LAB Position: Q4 2020 in Review

Jacobs Levy Equity Management sold out of Standard BioTools (LAB) in Q4 2020, closing a stake of 253,538 shares — an estimated $1.88M sold.

Jacobs Levy Equity Management first reported a position in LAB in Q1 2016 and held it in 19 quarters. The position peaked at $3.75M in Q1 2019. 145 funds tracked by Wall St. Rank hold LAB as of Q4 2020.

  • Jacobs Levy Equity Management reported no remaining Standard BioTools position as of Q4 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 253,538 Standard BioTools shares in Q4 2020, an estimated $1.88M.
  • Jacobs Levy Equity Management first reported a position in Standard BioTools in Q1 2016 and held it in 19 quarters.
  • Jacobs Levy Equity Management's Standard BioTools position peaked at $3.75M in Q1 2019.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.